Liver medicine – Rogalevich http://rogalevich.org/ Thu, 22 Sep 2022 05:29:22 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://rogalevich.org/wp-content/uploads/2021/10/icon-120x120.png Liver medicine – Rogalevich http://rogalevich.org/ 32 32 Cardiovascular disease risk factors largely the same for women and men, study finds https://rogalevich.org/cardiovascular-disease-risk-factors-largely-the-same-for-women-and-men-study-finds/ Thu, 22 Sep 2022 01:03:00 +0000 https://rogalevich.org/cardiovascular-disease-risk-factors-largely-the-same-for-women-and-men-study-finds/ For women and men, the risk factors for cardiovascular disease are largely the same, according to a large global study involving the University of Gothenburg. The study, now published in The Lancet, includes participants from both high-income and middle- and low-income countries. Cardiovascular diseases are more prevalent in the latter. Data are from the Prospective […]]]>

For women and men, the risk factors for cardiovascular disease are largely the same, according to a large global study involving the University of Gothenburg.

The study, now published in The Lancet, includes participants from both high-income and middle- and low-income countries. Cardiovascular diseases are more prevalent in the latter. Data are from the Prospective Urban and Rural Epidemiological Study (PURE).

The study included 155,724 people in 21 countries, on five continents. Aged between 35 and 70, the participants had no history of cardiovascular disease when they joined the study. All fatal cases of cardiovascular disease, heart attacks, strokes and heart failure during the follow-up period, which averaged ten years, were recorded.

The risk factors studied were metabolic (such as high blood pressure, obesity and diabetes), behavioral (smoking and diet) and psychosocial (economic status and depression).

No clear difference between gender or income

Metabolic risk factors were found to be similar in both sexes, with the exception of elevated low-density lipoprotein (LDL, often called bad cholesterol) values, where the association with cardiovascular disease was stronger in men. In the opinion of the researchers, however, this finding needs to be confirmed by further studies.

Depressive symptoms were another risk factor for cardiovascular disease that was found to be more important in men than in women. In contrast, the link between poor diet and cardiovascular disease was stronger in women; and smoking, although significantly more common in men, was an equally harmful risk factor for women.

Overall, the researchers found broadly similar cardiovascular disease risk factors for male and female participants, regardless of their country’s income level. This also highlights the importance of disease prevention strategies, which are the same for both genders.

Similarities greater than differences

The lower overall risk of cardiovascular disease in women, particularly heart attack (myocardial infarction), may be explained by younger women’s higher tolerance to risk factors. Their estrogens make vessel walls more flexible and affect the liver’s ability to get rid of LDL.

Among the women in the study (90,934 people), 5.0 cases of stroke, heart attack and/or cardiovascular disease were recorded per 1,000 people per year. The corresponding number in the male group (64,790 individuals) was 8.2 cases.

Annika Rosengren, Professor of Medicine at Sahlgrenska Academy, University of Gothenburg, is the study’s second author, in charge of the Swedish part of the PURE population study of 4,000 individuals in Gothenburg and Skaraborg.

When it comes to cardiovascular disease in men and women, the similarities in terms of risk factors are considerably more important than the differences. But men are more vulnerable to high levels of LDL, the bad cholesterol, and we know from other studies that they develop pathological changes in the coronary arteries at a younger age than women, and tend to develop a myocardial infarction much earlier. When it comes to early stroke, however, the gender differences are less pronounced, as we have also found in other studies.


Annika Rosengren, Professor of Medicine at Sahlgrenska Academy, University of Gothenburg

Source:

Journal reference:

Walli-Attaei, M., et al. (2022) Metabolic, behavioral and psychosocial risk factors and cardiovascular disease in women compared to men in 21 high-, middle- and low-income countries: an analysis of the PURE study. The Lancet. doi.org/10.1016/S0140-6736(22)01441-6.

]]>
Live better longer; avoid medical debt from chronic illness – Butler County Times-Gazette https://rogalevich.org/live-better-longer-avoid-medical-debt-from-chronic-illness-butler-county-times-gazette/ Mon, 19 Sep 2022 21:01:02 +0000 https://rogalevich.org/live-better-longer-avoid-medical-debt-from-chronic-illness-butler-county-times-gazette/ By Dr. Michael Roizen Q: I heard that life expectancy is declining in the United States. What can I do to make sure I live as long and healthy as possible? Mark R., Terra Haute, Indiana A: You’re right. Between COVID-19, opioids and fentanyl, Americans are dying younger. A new report from the Centers for […]]]>

By Dr. Michael Roizen

Q: I heard that life expectancy is declining in the United States. What can I do to make sure I live as long and healthy as possible? Mark R., Terra Haute, Indiana A: You’re right. Between COVID-19, opioids and fentanyl, Americans are dying younger. A new report from the Centers for Disease Control and Prevention found that life expectancy fell nearly two years for all 50 states and DC in 2020 – the biggest drop since World War II. Nationally in 2020, life expectancy at age 65 ranged from an additional 16.1 years in Mississippi to an additional 21.0 years in Hawaii. And New York has seen the biggest drop in life expectancy: in 2020, residents were expected to live three years less than in 2019.

The great irony is that at the same time, we are on the cusp of a revolution in our ability to significantly extend a high quality life. My new book, “The Great Age Reboot” is a blueprint for extending your life and your quality of life.

It brings together: 1. the steps you can take today; 2. the breakthrough science emerging on immunology, stem cells, cell reengineering, and 3. the importance of planning for a financially and emotionally extended future. To help you with this, there is a whole section on the “Science of Self Engineering” which helps you make good decisions about food, supplements, family, friends, your sex life, your future physical abilities (vision, hearing, balance, muscle strength), how you train and finance your future.

With all the challenges we face today, I remain convinced that each of you has the ability to shape the best possible future for yourself and your loved ones. Join me in the book on an exploration of your genetic self-engineering powers by adopting a plant-based, red meat-free diet; do at least 300 minutes of physical activity per week (I think 60 minutes per day is a good goal); embrace friends, family and passions; and make financial decisions that protect the future.

*** Q: My dad is 61, has heart failure and diabetes and is pretty depressed because his bills keep piling up. I’m doing what I can to make it easier for him and I want to make sure I don’t end up overwhelmed with illness and debt at his age. Ideas ? — Lloyd W., Birmingham, Alabama A: There is a direct link between chronic disease and financial problems. That’s according to a study published in JAMA Internal Medicine that looked at more than 2,800,000 adults, some of whom suffered from cancer, congestive heart failure, kidney disease, dementia, depression, anxiety, diabetes, high blood pressure, ischemic heart disease, liver disease, chronic obstructive lung disease and asthma, serious mental illness, stroke and substance use disorders. The researchers found that the more chronic conditions a person had, the more likely they were to go into debt. In the study group, 17.7% suffered from one chronic disease, 14.8% had two to three, 5.4% had four to six and 0.7% suffered from seven to 13 chronic diseases. Overall, about one-third of people with the most chronic conditions had medical debt and nearly half had outstanding debt for various reasons.

The bottom line: If you want to avoid debt, make choices to stay healthy! And, since most chronic diseases are the result, at least in part — if not entirely — of lifestyle choices, you’re in control! As I discuss in my new book, “The Great Age Reboot,” longevity and quality of life depend not only on smart health decisions, but also on smart financial decisions. This study shows how closely these two important steps are linked. As a young adult, you want to make sure your LDL cholesterol and blood pressure levels are healthy, your weight is under control, you get moderate to vigorous exercise, you don’t smoke, you don’t consume no or moderate alcohol, get seven hours of sleep each night, and save at least 3% of your annual income in a tax-sheltered account.

Health pioneer Michael Roizen, MD, is director emeritus of wellness at the Cleveland Clinic and author of four New York Times #1 bestselling books. His next book is “The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow”. Do you have a topic that Dr. Mike should address in a future column? If so, please email questions@Great-AgeReboot.com.

]]>
Optimizing Urgent Care Processes Improves Outcomes for Hospitalized HE Patients https://rogalevich.org/optimizing-urgent-care-processes-improves-outcomes-for-hospitalized-he-patients/ Fri, 16 Sep 2022 20:54:45 +0000 https://rogalevich.org/optimizing-urgent-care-processes-improves-outcomes-for-hospitalized-he-patients/ Patients with hepatic encephalopathy (HE) often do not seek care until they are in critical condition, making an optimized urgent care process essential to reduce adverse prognoses and improve clinical symptoms . According to a study published in International emergency medicine. HE is the loss of brain function due to chronic, severe liver disease, which […]]]>

Patients with hepatic encephalopathy (HE) often do not seek care until they are in critical condition, making an optimized urgent care process essential to reduce adverse prognoses and improve clinical symptoms .

According to a study published in International emergency medicine.

HE is the loss of brain function due to chronic, severe liver disease, which occurs when a damaged liver cannot remove toxins from the blood. Appropriate emergency care for patients with HE can improve their prognosis and quality of life, the authors wrote.

“Because [HE] often begins insidiously, most patients do not seek treatment until the advanced stage of the disease, when they are mostly in critical condition with complex changes, and if emergency care is not timely or inappropriate, they can affect the quality of life of patients in the later stages, and in severe cases, it can be life-threatening,” they explained.

Although standardized emergency procedures are crucial when treating HE, the lack of a unified process led to delays in resuscitation time, the authors added. In their study, they compared the outcomes of HE patients receiving conventional nursing emergency procedures with those receiving optimized nursing emergency procedures.

A total of 66 patients admitted to Xiangya Second Hospital in China between May 2020 and February 2022 were included in the study. Half (33 cases) were in the control group given the convention process and the remaining 34 cases were the observation group given the optimized process.

The control group process included:

  • General emergency measures
  • When the condition stabilized, the patient’s vital signs, major symptoms and physical signs were closely monitored
  • Nursing staff reassessed patient and applied medication for hepatic encephalopathy, treated primary disease

The observation group process included:

  1. The consultation process has been optimized with the direct sending of the patient to the resuscitation room
  2. The ambulance process has been optimized with an integrated pre-hospital ambulance
  3. The patient’s physical condition and vital signs were reassessed every 10 to 15 minutes
  4. The emergency department held monthly meetings to summarize problems nurses witnessed and to improve the level of emergency nursing staff.

Compared to patients in the control group, patients who received the optimized process spent less time on diagnosis, resuscitation, and referral to appropriate care teams. In the control group, there was a success rate of 93.7%: 26 patients were discharged with a cure, 4 patients were discharged with an improvement and 2 died due to ineffective first aid. In the observation group, the success rate was 100%, with no patient dying; 29 patients were discharged with healing and 5 patients were discharged with improvement.

The researchers also found that scores related to quality of ambulance technique, humanistic care, resuscitation efficiency and resuscitation effect were significantly higher for the group receiving care optimized by compared to the control group (P < .05).

Satisfaction of the families of treated patients was also higher in the observation group. In the control group, less than half (46.88%) said they were very satisfied with clinical care, compared to more than three quarters (76.47%) in the observation group. Only 5.88% of families in the observation group said they were dissatisfied with nursing care compared to 28.13% in the control group. The overall satisfaction rate of the control group was 71.88% against 94.12% in the observation group.

“After optimizing the emergency care process, a standard emergency care process can reduce unnecessary ties, and the patient’s condition can be systematically, comprehensively and timely assessed to avoid delaying the time emergency because of the multidisciplinary consultation, which can not only improve the resuscitation success rate but also improve the resuscitation effect,” the authors wrote.

Reference

Wei F, Tan H, He Y, Xin S. Impact of emergency care process optimization on urgency effect and prognosis of patients with hepatic encephalopathy. Emergency Med Int. 2022;2022:4446215. doi:10.1155/2022/4446215

]]>
Pfizer Vaccine Significantly Reduces Long-Term Covid Risk; Jynneos subcutaneous gives strong antibody response https://rogalevich.org/pfizer-vaccine-significantly-reduces-long-term-covid-risk-jynneos-subcutaneous-gives-strong-antibody-response/ Wed, 14 Sep 2022 13:08:30 +0000 https://rogalevich.org/pfizer-vaccine-significantly-reduces-long-term-covid-risk-jynneos-subcutaneous-gives-strong-antibody-response/ Learn about the biggest pharmaceutical developments and pricing stories from the past week in KHN’s Prescription Drug Watch roundup. CIDRAP: COVID vaccine can reduce long-term symptoms by up to 80% COVID-19 patients who had received two doses of the Pfizer/BioNTech vaccine reported 8 of the 10 most common symptoms of the long COVID 50% to […]]]>

Learn about the biggest pharmaceutical developments and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.

CIDRAP: COVID vaccine can reduce long-term symptoms by up to 80%

COVID-19 patients who had received two doses of the Pfizer/BioNTech vaccine reported 8 of the 10 most common symptoms of the long COVID 50% to 80% less often than their unvaccinated counterparts, according to an ongoing Israeli study published in the Nature journal npj Vaccines. (Van Beusekom, 9/12)

CIDRAP: Data from vaccine maker Monkeypox show strong response

Contrary to a recent Dutch preprint that questioned the efficacy of Bavarian Nordic’s Jynneos (modified vaccine Ankara [MVA]) to produce important neutralizing antibodies against monkeypox, the company published its own preliminary study showing that single-dose and two-dose Jynneos vaccines administered subcutaneously induced long-lasting neutralizing antibody responses in healthy volunteers. (Soucheray, 9/12)

The Washington Post: Ketamine shown to curb suicidal thoughts in new research

Throughout his 15-year battle with depression, Anthony, 52, could barely get out of bed. He kept empty one-liter soda bottles nearby when he couldn’t get to the bathroom. Showering and walking out the front door was a feat. He wouldn’t have thought to have fun with a tune. (Kornfield, 9/12)

ScienceDaily: Researchers develop messenger RNA therapy for ovarian cancer and muscle wasting

Researchers have developed a promising and first-of-its-kind messenger RNA therapy for ovarian cancer as well as cachexia, a muscle wasting condition associated with cancer and other chronic diseases. (Oregon State University, 9/13)

North Carolina Health News: Counterfeit pills more common in street drug supply

These days, if you buy a pill on the street, it’s most likely a counterfeit. Even if a pill says “Xanax” on it – unless purchased directly from a pharmacy – it’s probably something else. (Knopf, 9/6)

New England Journal of Medicine: Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma

In a pilot study involving patients with cutaneous squamous cell carcinoma, a high percentage of patients achieved a pathological complete response with the use of two doses of neoadjuvant cemiplimab prior to surgery. (Gross, MD, et al, 9/12)

The Gainesville Sun: Behavioral treatments for sleep disorders more effective than sleeping pills

The use of drugs to treat sleep disorders has dropped dramatically in the United States in recent years after several decades of strong growth, according to a study by a team of researchers led by a scientist from the University of Florida. (Mallard, 9/11)

Stat: Akero Drug for NASH reduces liver scarring, goal of mid-stage study

Akero Therapeutics said on Tuesday an experimental drug improved liver scarring twice as fast as a placebo without worsening other symptoms, meeting the primary goal of a mid-stage clinical trial involving patients with fatty liver disease. liver disease known as NASH. (Feuerstein, 9/13)

Modern healthcare: savings on Humira biosimilars could be delayed

Humira, the anti-inflammatory and rheumatoid arthritis biologic drug that has earned AbbVie nearly $200 billion in sales, has enjoyed nearly two decades of exclusivity, allowing the manufacturer to raise the price by 470% since introduction of the drug. The monopoly will end with the introduction of several Food and Drug Administration-approved copycat versions slated to hit the market in 2023, with more on the way. (Kacik, 9/13)

Stat: How drugmakers are turning telehealth into a marketing goldmine

A familiar refrain resounds in drug advertisements in the United States. You hear it at the end of TV spots and on the pages of magazines: Ask your doctor if this medicine is right for you. But as medicine increasingly moves online, direct-to-consumer advertising is adopting a more assertive slogan: Talk to a doctor now. (Palmer, 09/14)

This is part of the KHN Morning Briefing, a summary of health policy coverage by major news outlets. Sign up for an email subscription.

]]>
US Joint Board on Cancer Appoints Dhanpat Jain, MD, to Editorial Board https://rogalevich.org/us-joint-board-on-cancer-appoints-dhanpat-jain-md-to-editorial-board/ Mon, 12 Sep 2022 20:00:14 +0000 https://rogalevich.org/us-joint-board-on-cancer-appoints-dhanpat-jain-md-to-editorial-board/ Dhanpat Jain, MD, professor of pathology and medicine (digestive diseases), was appointed by the American Joint Committee on Cancer (AJCC) to its editorial board for neuroendocrine tumors of the gastrointestinal tract. The AJCC, founded in 1959, has developed and compiled cancer staging systems that are considered the bible of staging for all cancers, and has […]]]>

Dhanpat Jain, MD, professor of pathology and medicine (digestive diseases), was appointed by the American Joint Committee on Cancer (AJCC) to its editorial board for neuroendocrine tumors of the gastrointestinal tract.

The AJCC, founded in 1959, has developed and compiled cancer staging systems that are considered the bible of staging for all cancers, and has experts from all fields specializing in the staging of various cancers. The board is composed primarily of expert oncologists, surgical oncologists, radiologists and pathologists.

Dr. Jain is a nationally and internationally recognized gastrointestinal pathologist known for his diagnostic, research and teaching skills. He has over 150 publications, numerous book chapters, books and reviews, all of which are broadly in the field of gastrointestinal and hepatic pathology, and has lectured extensively and participated in numerous courses nationally and internationally. .

Cancer staging is the process of determining how much cancer is in the body and where it is. The AJCC cancer staging benchmarks are accepted and used by the medical profession to select the most effective treatment, determine prognosis, and continually evaluate cancer control measures.

Understanding the stage of cancer helps doctors establish a prognosis and design a treatment plan for each patient. It also helps identify clinical trials that may be appropriate for particular patients.

The AJCC Directing Handbook is updated periodically and currently on the 8e the edition is followed. However, the committee is currently working on the 9e edition, which will make substantial changes not only to staging protocols and how they are published for clinical use, but also to the format of the manual.

]]>
Scientists are developing a better type of chemotherapy https://rogalevich.org/scientists-are-developing-a-better-type-of-chemotherapy/ Sat, 10 Sep 2022 20:47:01 +0000 https://rogalevich.org/scientists-are-developing-a-better-type-of-chemotherapy/ Researchers have found two compounds that are more potent and less toxic than existing leukemia treatments, which often cause unpleasant side effects in patients. Researchers are discovering a new class of drugs that offer leukemia patients a safer, more targeted form of treatment. Chemotherapy is no fun. It’s no secret that the drugs used in […]]]>

Researchers have found two compounds that are more potent and less toxic than existing leukemia treatments, which often cause unpleasant side effects in patients.

Researchers are discovering a new class of drugs that offer leukemia patients a safer, more targeted form of treatment.

Chemotherapy is no fun. It’s no secret that the drugs used in treatments often have harmful side effects on the patient and their cancer. Since tumors grow so quickly, the theory is that chemotherapy will eradicate the disease before its adverse effects take the life of the patient. For this reason, researchers and medical professionals are always looking for more effective treatments.

Researchers from the University of California, Santa Barbara, along with colleagues from the University of California, San Francisco and Baylor College of Medicine, have discovered two compounds that are both more potent and less toxic than current therapies for cancer. leukemia. The molecules work in a way that differs from conventional cancer treatments and may form the basis of an entirely new class of drugs.

Additionally, the compounds are already approved for the treatment of other diseases, greatly reducing the amount of paperwork required to modify them for the treatment of leukemia or even to administer them off-label. The results were recently published in the Journal of Medicinal Chemistry.

“Our work on an enzyme that is mutated in leukemia patients has led to the discovery of an entirely new way to regulate this enzyme, as well as new molecules that are more efficient and less toxic to human cells,” said the professor emeritus at UC Santa Barbara. Norbert Reich, the corresponding author of the study.

DNMT3A enzymes

A pair of DNMT3A enzymes joins two helper proteins (green) to form a four-part complex that moves along DNA adding chemical tags that tell a cell which genes to express. Credit: Jonathan Sandoval et al.

The epigenome

Although every cell in your body has the same DNA, or genome, depending on what type of cell it is, each uses a different part of this blueprint. This allows different cells to perform their specific tasks while using the same instruction manual; in reality, they just use different sections of it. The epigenome tells cells how to follow these instructions. Chemical markers, for example, control which sections are read and therefore dictate the actual fate of a cell.

A cell’s epigenome is copied and preserved by an enzyme (a type of protein) called DNMT1. This enzyme ensures, for example, that a dividing liver cell becomes two liver cells and not one brain cell.

However, even in adults, some cells have to differentiate into different cell types than they did before. For example, bone marrow stem cells are able to form all different types of blood cells, which do not reproduce on their own. This is controlled by another enzyme, DNMT3A.

All is well until something goes wrong with DNMT3A causing the bone marrow to turn into abnormal blood cells. It is a primary event leading to various forms of leukemia, as well as other cancers.

Toxic treatments

Most cancer drugs are designed to selectively kill cancer cells while leaving healthy cells alone. But it is extremely difficult, which is why so many of them are extremely poisonous. Current leukemia treatments, such as decitabine, bind to DNMT3A in a way that deactivates it, thereby slowing disease progression. They do this by obstructing the active site of the enzyme (essentially, its business activity) to prevent it from performing its function.

Unfortunately, the active site of DNMT3A is virtually identical to that of DNMT1, so the drug shuts down epigenetic regulation in all 30-40 trillion cells in the patient. This leads to one of the biggest bottlenecks in the pharmaceutical industry: off-target toxicity.

Obstructing the active site of a protein is an easy way to knock it offline. That’s why the active site is often the first place drug designers look when designing new drugs, Reich explained. However, about eight years ago he decided to investigate compounds that could bind to other sites to avoid off-target effects.

Work together

As the group investigated DNMT3A, they noticed something peculiar. While most of these epigenetic-related enzymes function alone, DNMT3A has always formed complexes, either with itself or with partner proteins. These complexes can involve more than 60 different partners and, interestingly, they act as guidance devices to direct DNMT3A to control particular genes.

Early work in the Reich lab, led by former graduate student Celeste Holz-Schietinger, showed that disrupting the complex with mutations did not interfere with its ability to add chemical markers to DNA. However, DNMT3A behaved differently when singly or in a single pair; it was not about staying on the DNA and marking one site after another, which is essential for its normal cellular function.

Around the same time, the New England Journal of Medicine conducted an extensive analysis of the mutations present in leukemia patients. The authors of this study found that the most common mutations in patients with acute myeloid leukemia are in the DNMT3A gene. Surprisingly, Holz-Schietinger had studied the exact same mutations. The team now had a direct link between DNMT3A and epigenetic changes leading to acute myeloid leukemia.

Discover a new treatment

Reich and his group were interested in identifying drugs that could interfere with the formation of DNMT3A complexes that occur in cancer cells. They obtained a chemical library containing 1,500 previously studied drugs and identified two that disrupt DNMT3A’s interactions with partner proteins (protein-protein inhibitors or PPIs).

Furthermore, these two drugs do not bind to the active site of the protein, so they do not affect DNMT1 at work in all other cells in the body. “This selectivity is exactly what I hoped to discover with the students on this project,” Reich said.

These drugs are more than just a potential breakthrough in the treatment of leukemia. These are a whole new class of drugs: protein-protein inhibitors that target a part of the enzyme away from its active site. “An allosteric PPI has never been done before, at least not for an epigenetic drug target,” Reich said. “It really made me smile when we got the result.”

This achievement is no small feat. “Developing small molecules that disrupt protein-protein interactions has proven challenging,” noted lead author Jonathan Sandoval of UC San Francisco, a former doctoral student in Reich’s lab. “These are the first reported inhibitors of DNMT3A that disrupt protein-protein interactions.”

The two compounds identified by the team have already been used clinically for other diseases. This eliminates a lot of the cost, testing, and bureaucracy involved in developing them into leukemia therapies. In fact, oncologists could prescribe these drugs to off-label patients now.

Building on success

There’s still more to understand about this new approach, however. The team wants to learn more about how protein-protein inhibitors affect DNMT3A complexes in healthy bone marrow cells. Reich is collaborating with UC Santa Barbara chemistry professor Tom Pettus and one of their doctoral students, Ivan Hernandez. “We are making changes to the drugs to see if we can further improve selectivity and potency,” Reich said.

There is also more to learn about the long-term effects of medications. Since the compounds act directly on enzymes, they might not alter the underlying cancer-causing mutations. This warning affects how doctors can use these drugs. “One approach is for a patient to continue on low doses,” Reich said. “Alternatively, our approach could be used with other treatments, perhaps to reduce tumor burden to a point where stopping treatment is an option.”

Reich also admits that the team has yet to learn what effect PPIs have on long-term bone marrow differentiation. They are curious whether drugs can elicit some type of cellular memory that could alleviate problems at the epigenetic or genetic level.

That said, Reich is excited about their discovery. “By not targeting the active site of DNMT3A, we are already miles beyond the currently used drug, decitabine, which is definitely cytotoxic,” he said, adding that this type of approach could also be suitable for other cancers.

Reference: “First-class allosteric inhibitors of DNMT3A disrupt protein-protein interactions and induce cellular differentiation in acute myeloid leukemia” by Jonathan E. Sandoval, Raghav Ramabadran, Nathaniel Stillson, Letitia Sarah, Danica Galonić Fujimori, Margaret A. Goodell and Norbert Reich, July 22, 2022, Journal of Medicinal Chemistry.
DOI: 10.1021/acs.jmedchem.2c00725

]]>
Akero Therapeutics to Present Phase 2b HARMONY Results https://rogalevich.org/akero-therapeutics-to-present-phase-2b-harmony-results/ Thu, 08 Sep 2022 20:01:00 +0000 https://rogalevich.org/akero-therapeutics-to-present-phase-2b-harmony-results/ SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with severe metabolic disease marked by need unsatisfied medical high, will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, […]]]>

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with severe metabolic disease marked by need unsatisfied medical high, will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).

Conference Call/Webcast Details
The company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Tuesday, September 13. Please click here to register for the event. The live webcast will be available on the Events & Presentations page of Akero’s website, with the recording and presentation available immediately following the event.

About NASH
NASH (non-alcoholic steatohepatitis) is a severe form of NAFLD (non-alcoholic fatty liver disease) estimated to affect 17 million Americans. NASH is characterized by excessive fat accumulation in the liver that causes stress and damage to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. There is no approved treatment for the disease, and NASH is one of the leading causes of liver transplants in the United States and Europe.

About the HARMONY Study
The Phase 2b HARMONY study is a multicenter, randomized, double-blind, placebo-controlled, dosing trial in biopsy-confirmed adult patients with pre-cirrhotic NASH, fibrosis stage 2 or 3. The study recruited a total of 128 patients, randomized to receive once a week a subcutaneous dose of 28 mg or 50 mg of EFX, or a placebo. The primary efficacy endpoint of the study is the proportion of subjects who achieve at least one stage improvement in fibrosis without worsening of NASH at week 24. Additional secondary measures at week 24 include other liver histology endpoints; non-invasive markers of liver fibrosis; change from baseline in liver fat, liver enzymes, glycemic control, lipoproteins and body weight as well as safety and tolerability measures. To provide long-term safety data, patients will continue treatment with EFX or placebo for a follow-up period of up to 96 weeks.

About efruxifermin
Efruxifermin (EFX) is Akero’s lead product candidate for NASH, currently being evaluated in the ongoing HARMONY Phase 2b study. EFX is designed to reverse fibrosis, reduce liver fat and inflammation, increase insulin sensitivity, and improve lipoproteins. This holistic approach offers the potential to treat the complex, multi-system disease state of NASH, including improving lipoprotein risk factors for cardiovascular disease – the leading cause of death in NASH patients. Designed to mimic the biological activity profile of native FGF21, EFX offers convenient once-weekly dosing and has been generally well tolerated in clinical trials to date.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with severe metabolic diseases marked by significant unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease with no approved therapy. Akero’s lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that attenuates cellular stress and regulates metabolism throughout the body. EFX is designed to provide convenient once-weekly subcutaneous dosing. The consistency and magnitude of the observed effects positions EFX as a potentially best-in-class drug, if approved, for the treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with pre-cirrhotic NASH (fibrosis F2-F3) and the SYMMETRY study in patients with cirrhotic NASH (fibrosis F4, compensated). EFX is also being evaluated in an expansion cohort of the SYMMETRY study, comparing the safety and tolerability of EFX to placebo when added to an existing GLP-1 receptor agonist in patients with pre-NASH. – cirrhosis (fibrosis F1-F3) and type 2 diabetes. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and Twitter for more information.

Forward-looking statements
Statements in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero’s business plans and objectives, including plans or future expectations for efruxifermin (EFX), the therapeutic effects of EFX, as well as the dosage, safety and tolerability of EFX; and next steps, including results, and the expected timeline for reporting these results from Akero’s Phase 2b HARMONY study. All forward-looking statements contained in this press release are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. statements. Risks that contribute to the uncertain nature of forward-looking statements include: risks relating to the impact of COVID-19 on Akero’s current and future operations, including potential adverse impacts on Akero employees, third parties , manufacturers, supply chain and production as well as global economies and financial markets; the success, cost and timing of Akero’s product candidate development activities and planned clinical trials; Akero’s ability to execute its strategy; positive results from a clinical study are not necessarily predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero’s ability to fund operations; as well as the risks and uncertainties discussed in more detail under “Risk Factors” in Akero’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as filed with the Securities and Exchange. Commission (SEC) as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor contacts:
Christine Tartaglia
212.362.1200
IR@akerotx.com

Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com

]]>
Study offers potential diagnostic and therapeutic tools for fatty liver disease-induced diabetes https://rogalevich.org/study-offers-potential-diagnostic-and-therapeutic-tools-for-fatty-liver-disease-induced-diabetes/ Wed, 07 Sep 2022 05:08:20 +0000 https://rogalevich.org/study-offers-potential-diagnostic-and-therapeutic-tools-for-fatty-liver-disease-induced-diabetes/ Non-alcoholic fatty liver disease and type 2 diabetes are rising rapidly in India The researchers analyzed blood samples from fat-fed mice and human NAFLD patients. Representative photo: India Science Wire A new study by a team of researchers from several Indian institutions has revealed the biochemical relationship between fatty liver disease and type 2 diabetes […]]]>

Non-alcoholic fatty liver disease and type 2 diabetes are rising rapidly in India

The researchers analyzed blood samples from fat-fed mice and human NAFLD patients. Representative photo: India Science Wire

A new study by a team of researchers from several Indian institutions has revealed the biochemical relationship between fatty liver disease and type 2 diabetes mellitus (T2DM). This understanding should help develop new tools to diagnose and treat diabetes induced by fatty liver disease.

The study is gaining significance as the prevalence of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes is rapidly increasing in India. Recent surveys show that 40% of Indian adults suffer from NAFLD and nearly 50 million Indian adults suffer from both NAFLD and type 2 diabetes.

The study team consisted of researchers from Indian Institute of Technology Mandi, CSIR-Indian Institute of Chemical Biology, Kolkata, and Institute of Post Graduate Medical Education & Research (SSKM Hospital), Kolkata. They published a report on their findings in the scientific journal Diabetes.

Explaining the importance of their work, the researchers noted that NAFLD affecting the function of pancreatic insulin-releasing β cells was a known fact. But the mechanism has not been fully understood. The new study has filled the void.

The researchers analyzed blood samples from fat-fed mice and human NAFLD patients. Both sets of serum samples contained large amounts of a calcium-binding protein called S100A6, and other studies have shown that it inhibits insulin secretion. Other studies have shown that protein depletion improves insulin secretion and blood sugar regulation in mice.

The researchers said the study was critical in many ways. From a diagnostic point of view, it shows that high levels of S100A6 protein in the blood can serve as a biomarker to identify the risks of T2DM in NAFLD patients. At the therapeutic level, it has been shown that its removal from the blood can help restore insulin secretion.

The team consisted of Dr. Prosenjit Mondal, Associate Professor, School of Biosciences and Bioengineering, IIT Mandi, with its researchers Surbhi Dogra, Priya Rawat, Dr. P Vineeth Daniel, Dr. Partha Chakrabarti from CSIR-Indian Institute of Chemical Biology, Kolkata and his colleagues Dr DebajyotiDas, Sujay K Maity and Avishek Paul and Dr Kausik Das and Dr Souveek Mitra from IPGMER and SSKM Hospital, Kolkata. (India ScienceWire)




]]>
Who is Liver King? Know His Ridiculous Liver Diet https://rogalevich.org/who-is-liver-king-know-his-ridiculous-liver-diet/ Sun, 04 Sep 2022 10:59:40 +0000 https://rogalevich.org/who-is-liver-king-know-his-ridiculous-liver-diet/ Instagram is flooded with influencers who post reels, stories and photos about different things to influence and inspire their followers. Flu culture on social media platforms has become a huge hit. After all, these people not only become famous, they also manage to earn money. While lots of people are talking about fashion, fitness, travel […]]]>

Instagram is flooded with influencers who post reels, stories and photos about different things to influence and inspire their followers. Flu culture on social media platforms has become a huge hit. After all, these people not only become famous, they also manage to earn money.

While lots of people are talking about fashion, fitness, travel and lifestyle, one Instagram influencer begs to differ. This one is a muscular, bearded man who lifts crazy weights. Well, lifting weights and posting videos and photos is normal. However, what makes him different from other social media influencers is that he eats ridiculous amounts of raw meat!!!!

Yes, you heard right.

This IG influencer calls himself the liver king. He prefers to live his own way, as he does not like to resort to a modern way of life but prefers an older way of living and eating.

The liver king eats animal liver every day. Here’s everything you need to know about him and his approach to fitness and a healthy lifestyle.

Who is Liver King?

Liver King’s real name is Brian Johnson. She is a social media personality who urges all of her followers to live a Ancestral lifestyle be in good physical and mental health. He calls himself Liver King out of love for eating animal liver. According to him, it is a nutritionally dense food source.

Why does Liver King follow a bizarre act of eating liver?

There’s a reason Liver King likes to feed on raw liver. He claims that the modern world has made men extremely soft and fragile. The only way to change it is to live more like our ancestors.

Thus, to achieve this, he recommends his disciples to follow the nine ancestral principles he has set himself. It also motivates them to do heavy training and eat raw liver to stay healthy.

What are the ancestral principles of which Liver King speaks?

The self-proclaimed Liver King designed his Ancestral program, and he’s spreading the word on all social media platforms. According to him, “The human body has been perfectly conditioned for an environment that no longer exists. By living ancestrally, we overcome the obstacles between us and true health and happiness. We are rewriting the disconnect between who we are and the environment in which we live.

Here are the nine ancestral principles he raves about.

Sleep

According to him, it is necessary to improve the quality of his sleep by relaxing early in the evening. The Liver King also suggests eating the last meal of the day several hours before you go to bed and not using your phone to sleep.

To eat

He urges his followers to cut out processed foods, seed oils and liquid calories from their diets because all of these are detrimental to good health.

Move

The Liver King takes three 30-minute walks a day. According to him, “The well-being that is built from a balanced movement outweighs the need for satisfaction based on consumption.

Shield

You have to protect yourself from the dangers that modern life inflicts, such as fluoride, Wi-Fi and seed oils. The Liver King states that these are real dangers that end up making your life worse with an additive effect. They also disrupt your hormones, your metabolism, and your ability to sleep well.

Relate

Connecting with nature is part of the ancestral principle launched by the King of the Liver. He suggests taking off the shoes, going for a walk and connecting to the earth. It helps improve blood pressure and sleep quality.

Cold

Another thing Liver King suggests is the use of ice baths. According to him, jumping into cold rivers and lakes or taking a cold shower helps improve blood circulation. It also strengthens the body’s resilience to stress.

Sun

Getting enough sunlight is another essential aspect, as it provides vitamin D which works in synergy with other fat-soluble vitamins A and K.

Struggle

No. Liver king doesn’t mean fighting with the neighborhood guy. But he suggests setting goals and aspirations and striving to achieve them. It releases dopamine and makes you happy.

Obligation

According to Brian, the purpose of our ancestors was to protect the people around them by building shelters and hunting for food. He admits that the world doesn’t have to worry about these things so much anymore. However, he suggests putting away his phone and spending time with loved ones, friends and family. Ultimately, humans need humans.

You can explore more descriptions of these items on its website. According to a few people, many Liver King teachings are not necessarily radical ideas. However, when combined, they can bring a more fulfilling life.

How old is Liver King?

According to some reports, Liver King’s age is 44 in 2022.

What does the Liver King diet include?

The influencer gorges on about a pound of raw liver every day. This amount is far too high for most organ novices. So, he suggests that if someone wants to follow their diet, they should start with three ounces twice a week and gradually increase the serving. It also feeds on organs and muscle meats from grass-fed animals. Other items in his diet include egg yolks, whole raw milk and cheese, fish roe, homemade bone broth, and fermented vegetables.

He put on his website, “I’m not a hospital, I’m not a doctor, this is not medical advice. However, I have a degree in biochemistry.

According to many health experts, his diet is not healthy at all. Eating a pound of raw liver every day is dangerous, as it can lead to vitamin A toxicity.

What is Liver King net worth?

Liver King’s estimated net worth is one million dollars. The majority of his wealth comes from his supplement brands. The most popular brand he created is Ancestral supplements. He suggests that these supplements are for people who seek basic health and targeted support in tune with old-fashioned nature.

Other Liver King Health Tips

  • Keep your sleeping temperature between 64 and 68 degrees Fahrenheit and use blackout blinds because your bedroom should be completely dark while you sleep.
  • Use Himalayan salt lamps at sunset instead of regular lighting.
  • Wear UVEX protective eyewear 2-3 hours before going to bed.
  • Take a sleeping concoction 30 minutes before sleeping.
  • Get into the habit of sleeping on the floor like our ancestors did.

What do you think of the fitness and health approach suggested by Liver King? Tell us in the comments below.

]]>
Premature ovarian failure can lead to infertility https://rogalevich.org/premature-ovarian-failure-can-lead-to-infertility/ Sat, 03 Sep 2022 01:23:56 +0000 https://rogalevich.org/premature-ovarian-failure-can-lead-to-infertility/ Premature ovarian failure is one of the common gynecological diseases and the number of cases reported each year is increasing. There is also the tendency to view it as occurring at younger and younger ages. For young women, it not only affects fertility, but also has a significant impact on physical and mental health. He […]]]>

Premature ovarian failure is one of the common gynecological diseases and the number of cases reported each year is increasing. There is also the tendency to view it as occurring at younger and younger ages. For young women, it not only affects fertility, but also has a significant impact on physical and mental health. He Xiaoxia, a former TCM doctor from Shanghai, introduced a way to take care of female ovaries and prevent premature aging from the perspective of TCM. She suggested that for patients with premature ovarian failure, the best effect might come from TCM therapy combined with an appropriate supplemental diet.

For most women, ovarian function is at its peak around age 25 and begins to decline by age 30. After age 35, this decline begins to accelerate, until around age 48 to 50, when it enters a state of permanent decline and ceases to function. From then on, women gradually enter old age.

Such a decline is a manifestation of the ovarian aging process, known in the medical profession as “declining ovarian reserve”. Normal physiological ovarian aging is an irresistible law of nature. However, in recent years, studies have shown that more and more women before the age of 40 begin to show symptoms of ovarian failure, which is considered premature ovarian failure in such cases. Even cases found in teens and twenties are not uncommon. Such a trend is worth noting and sometimes disturbing, because it not only affects fertility, but also seriously affects the physical and mental health of women.

There are many symptoms of premature ovarian failure, including irregular menstrual cycles, which may be absent for several months, poor menstrual flow, infertility, menopausal symptoms such as hot flashes, abnormal heart rhythms , insomnia, anxiety and other symptoms. Due to associated hormonal changes, it is more likely to cause osteoporosis, hyperlipidemia, coronary artery disease, etc.

Probable causes of premature ovarian failure

So what are the factors that lead to premature ovarian failure? In an interview with The Epoch Times, Dr. He Xiaoxia, a former TCM doctor from Shanghai, pointed out that in general, the earlier the age of menarche (first onset of menstruation), the more ovarian function declines. early. It will be accelerated for those who have unhealthy habits such as smoking and heavy drinking. More at risk are those trying to maintain a slim figure, who sometimes prefer to put on tight underwear. This will put extra pressure on the body and will likely affect the normal development of the ovaries. In the worst case, it could also damage them, leading to premature aging.

Dr. He pointed out that, especially for teenage girls, wearing pantyhose is not only detrimental to the development of the body, but can also lead to the occurrence of diseases such as breast hyperplasia or cysts. Moreover, excessive psychological pressure in life and workplace, such as staying up late, etc., will also affect the health of ovarian function and make it more prone to premature ovarian failure.

TCM starts treatment from the kidneys

Dr. He said that in TCM, treatment for premature ovarian failure focuses primarily on the kidneys. This includes, tonifying the kidneys and invigorating blood flow, nourishing the kidneys from any deficiency, and simultaneously soothing the liver and regulating menstruation so that qi (life energy) and blood are full. With all of this in place, it can improve ovarian function and restore menstruation, to some extent. “In the treatment of premature ovarian failure, Chinese medicine does not limit itself to creating a favorable internal environment for pregnancy, it also seeks to improve various symptoms of menopause and promote recovery.”

Dr. He said, according to the “Huang Di Nei Jing (the first edition of TCM theories dated before the 2nd century BC). At 14, the age of menarche, the Ren meridian is opened, the Tai Chong meridian becomes fully developed, and then the menstrual period begins. Changes in menstrual physiology and female reproductive function are all governed by the kidneys, and its natural process of gradual maturity, followed by complete and gradual decline and exhaustion, exhibits a law of nature consistent with age. The normal functioning of menstrual physiology depends on the reconciliation of qi and blood from the viscera.

The kidneys are somehow intimately related to the heart, liver, spleen, and lungs. While the kidneys store the reserve of essence that the body needs, the liver stores blood and the spleen generates it. The heart controls blood flow, the lungs control qi, and qi carries blood. These few organs are therefore physically linked and interdependent with each other. Any deficiency in kidney yin (the inherent ingredient in dark matter), deficiency in qi or blood, or simply low qi in the kidneys could all be contributing factors to the onset of premature ovarian failure.

Dr He added that stress is also still a key factor. It will affect endocrine function, so we also need to pay attention to the need to soothe the liver. To make circulation smooth, eliminate phlegm, regulate qi and activate blood is almost indispensable. She introduced that the most commonly used medicinal substances for the treatment of premature ovarian failure include prepared Rehmannia root, Cuscuta chinensis, Angelica sinensis, Epimedium folium, Cornus officinalis, etc. A local TCM practitioner might advise you which one to try.

Best effect when combined with a suitable dietary supplement

The homology of drugs and foods plays a certain positive role in the treatment of premature ovarian failure. Dr. He suggested that patients with premature ovarian failure could also be supplemented with dietary therapy alongside traditional Chinese medicine treatment. In the diet, make sure that there are the necessary proteins, preferably high-quality ones, fats and carbohydrates. At the same time, proper supplementation of B-type vitamins, vitamin C, vitamin E, as well as trace elements zinc and calcium can support the female reproductive system well.

She suggested that patients should eat more nutritious colloidal animal parts such as chicken feet, pork skin, sea cucumber, and jellyfish skin; plants such as kelp, seaweed, yam, mushrooms (black or white), Kappaphycus, … Also pay attention to consuming less fat but high fiber foods, such as taking more natural fruits and vegetables, less ‘cold and raw food, because this type of food will cause damage to the “yang qi” of the spleen and stomach. This is especially the case for people born with symptoms of “yang qi” deficiency.

Dr. He pointed out that it doesn’t matter whether you are fat or thin, engaging in moderate physical activity can always improve your physique. It’s even better if the activities also involve pelvic movements. In this case, there is an improvement in metabolism and blood circulation through various organs of the body, which, to some extent, keeps the ovaries in better condition.

Follow

Ellen Wan has worked for the Japanese edition of The Epoch Times since 2007.

]]>